What's breaking now, across thousands of outlets.
Latigo Biotherapeutics said its non-opioid drug reduced acute pain in a Phase 2b study, as the company seeks to compete with Vertex Pharmaceuticals’ approved pain treatment Journavx. Next, Latigo has to replicate its findings in ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
"The actual harsh truth about MAHA is that it is an anti-vaxx, anti-science, pro-diarrhea conspiracy movement. It cloaks its arguments in abstractions about "big pharma" and "free speech" to generate…
"The actual harsh truth about MAHA is that it is an anti-vaxx, anti-science, pro-diarrhea conspiracy movement. It cloaks its arguments in abstractions about "big pharma" and "free speech" to generate…
[allAfrica] Rio de Janeiro, Brazil -- Evidence is growing that the people most affected by HIV are also the most vulnerable to the effects of climate change.
As the death toll rises to almost 1,500, and with a vaccine against the Bundibugyo strain potentially still months away, health workers face a battle to slow the outbreak The latest numbers of…
Today we welcome Gene Mack, President and CEO of Gain Therapeutics. Their lead candidate is advancing toward Phase 2 as a potential first-in-class disease-modifying therapy for Parkinson’s disease The…
Why NCISM says Ayurveda, Unani, Siddha, and Sowa-Rigpa doctors cannot be called “quacks”
